

I. Purpose

Instructions for the quantitative analysis of vancomycin in human serum or plasma on the Beckman Coulter AU Clinical Chemistry analyzers.

A	Principle
	<p>The Emit 2000 Vancomycin Assay is a homogeneous enzyme immunoassay technique used for the quantitative analysis of vancomycin in human serum or plasma. The assay is based on competition between drug in the sample and drug labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH) for antibody binding sites. Enzyme activity decreases upon binding to the antibody, so the drug concentration in the sample can be measured in terms of enzyme activity. Active enzyme converts oxidized nicotinamide adenine dinucleotide (NAD) to NADH, resulting in an absorbance change that can be measured spectrophotometrically. Endogenous serum G6PDH does not interfere because the coenzyme functions only with the bacterial (<i>Leuconostoc mesenteroides</i>) enzyme employed in the assay.</p>

B	Clinical Indication
	<p>Vancomycin is an aminoglycoside antibiotic used to treat infections caused by many different bacteria.</p> <p>Monitoring serum vancomycin concentrations, along with careful clinical assessment, is the most effective means of ensuring adequate therapy for several reasons:</p> <ol style="list-style-type: none"> 1. Individual patients exhibit a high degree of variability in response to a given dose of vancomycin in terms of the volume of distribution and the rate of drug clearance from plasma. 2. The risk of ototoxicity and nephrotoxicity from vancomycin is increased in patients with impaired renal function and in patients receiving concurrent aminoglycoside therapy. 3. Patients with impaired renal or hepatic function, dialysis patients, morbidly obese patients, patients receiving concurrent aminoglycoside therapy, and pediatric or elderly patients should be monitored closely while on vancomycin therapy.

II. Scope

All Testing Personnel, specifically Clinical Laboratory Scientists (CLS).

III. Safety Precautions

Testing personnel must take normal infectious disease precautions, including but not limited to PPE.

IV. Specimen

All blood should be handled as though potentially infectious. Follow laboratory bloodborne pathogen policy and guidelines when handling body fluid specimens.

A	Specimen Requirements
	1. Type: <ul style="list-style-type: none"> a. Serum (Plain Red top only) <ul style="list-style-type: none"> i. Separate serum/plasma from cells as soon as possible if testing is delayed. ii. Use of tubes with separator gel (SST or PST) should be avoided due to possible absorption of the drug by the gel.
	2. Sample Collection Time <ul style="list-style-type: none"> a. Peak: To obtain a vancomycin concentration that best represents the peak tissue level, draw the sample 0.5 - 2.0 hours after an infusion. b. Trough: Trough levels are reflected by samples obtained immediately prior to the next dose.
	3. Volume: <ul style="list-style-type: none"> a. Minimum - 0.5 mL b. Sample Size (dead space excluded) – 3 uL
	4. Stability: <ul style="list-style-type: none"> a. Refrigerated (2 - 8°C): 3 days b. Frozen (<-20°C): 30 days
	5. Unacceptable specimen: <ul style="list-style-type: none"> a. Whole blood b. Tubes with separator gel (SST or PST) <ul style="list-style-type: none"> i. In the event that SST/PST is received and redraw is not possible due to timed collection, append Result Comment TDMSSST "Specimen received in inappropriate draw tube. Results may be affected and should be interpreted with caution." Refer to reporting section.
	6. Special Handling: <ul style="list-style-type: none"> a. Samples that contain particulate matter, fibrous material, gel-like masses, appear unusual, or were frozen: <ul style="list-style-type: none"> i. If sample is frozen, thaw at room temperature (15-25°C). ii. Vigorously mix sample in a vortex for at least 30 seconds. iii. Centrifuge sample at > 2000 rpm for 15 minutes. iv. Collect a specimen from the middle portion of the sample. Avoid collecting lipids from the top portion or particulate matter from the bottom portion.

V. Equipment Calibration and Maintenance

A	Calibration
	1. Perform a multi-point calibration (5AB) using a water blank and the Emit tox Vancomycin Calibrators.

	2. Frequency: <ol style="list-style-type: none"> a. Every 10 days b. Each new set of reagent (recommended, but not required) c. When reagent lot changes d. When QC has shifted e. After major preventive maintenance, or replacement of a critical part
	3. Calibrator: Emit 2000 Vancomycin Calibrators (ug/mL) :0, 5, 10, 20, 30, 50.
	4. Preparation: <ol style="list-style-type: none"> a. Calibrators are packaged in a ready to use liquid form and may be used directly from the refrigerator. b. Record open dates and initials
	5. Storage and Stability <ol style="list-style-type: none"> a. Store at 2-8°C, upright, and with caps tightly closed when not in use. b. Unopened and opened calibrators are stable until the expiration date printed on the label if stored as directed. c. Do not freeze the calibrators or expose them to temperatures above 32°C.
B	Maintenance
	Refer to SFOFCD-0408. Refer to SFOWI-1268. Refer to AU680 Chemistry Analyzer User's Guide-Chapter (8) -Maintenance

VI. Supplies

<i>All reagents must be dated upon receipt and upon installation. The "on-board" expiration date must also be indicated on installed reagents.</i>				
A	Reagent			
	1. Preparation <ol style="list-style-type: none"> a. Reagents 1 and 2 are provided as a matched set. Do not interchange with components of kits with different lot numbers. 			
	Reagent	Ingredient	Concentration	Preparation
	R1 (Antibody/ Substrate)	Mouse monoclonal antibodies reactive to vancomycin G6P NAD Non-sterile bovine serum albumin stabilizers preservatives	N/A	Ready for use
	R2 (Enzyme)	Vancomycin labeled with bacterial G6PDH HEPES buffer Bovine serum albumin stabilizers preservatives	N/A	Ready for use

	2. Storage & Stability <ol style="list-style-type: none"> a. Opened bottle expiration date is monitored by the analyzer. b. Do not use the reagent kit or calibrators after the expiration date. c. Do not freeze reagents or expose them to temperatures above 32°C. 	
	Storage	Expiration Date
Unopened	2 - 8°C	Stable until expiration date on label
Opened	In refrigerated compartment of the analyzer	90 days Record open date & initials on bottle.
	3. Indications of Deterioration: <ol style="list-style-type: none"> a. Discoloration, especially yellowing, of the reagent, visible signs of microbial growth, turbidity or precipitation in reagent may indicate degradation and warrant discontinuance of use. 	
	4. Precautions: <ol style="list-style-type: none"> a. Reagents contain sodium azide preservatives. Flush with plenty of water when discarding reagents. 	

VII. Quality Control

A	QC Material & Stability
	Refer to SFOFCD-0407
B	Frequency
	<ol style="list-style-type: none"> 1. Two levels of QC every 24 hours 2. Each new reagent bottle (even if same Lot #) 3. Each new reagent lot 4. After every calibration 5. After each shipment of the same Lot # 6. After specific maintenance or troubleshooting as detailed in the operators manual or after service/repair.
C	Acceptability Criteria
	1. Refer to SFOWI-0218

VIII. Procedure

A	Sample Analysis
	1. Refer to SFOWI-1268 (AU680 General Operating Procedures)

B	Dilutions						
	<table border="1"> <tr> <td data-bbox="310 369 673 401">On-Board Auto Dilution</td> <td data-bbox="673 369 1050 401">Maximum Dilution</td> <td data-bbox="1050 369 1380 401">Diluent</td> </tr> <tr> <td data-bbox="310 401 673 451">X10</td> <td data-bbox="673 401 1050 451">X10</td> <td data-bbox="1050 401 1380 451">DI Water</td> </tr> </table>	On-Board Auto Dilution	Maximum Dilution	Diluent	X10	X10	DI Water
On-Board Auto Dilution	Maximum Dilution	Diluent					
X10	X10	DI Water					
	NOTE: On-board dilution = Maximum dilution						
	<ol style="list-style-type: none"> 1. Auto dilution: <ol style="list-style-type: none"> a. When results exceed the assay's AMR, an on-board auto-dilution is performed. Results are automatically multiplied by the instrument. 						
	<ol style="list-style-type: none"> 2. Manual dilution: N/A 						
C	Repeats						
	<ol style="list-style-type: none"> 1. Follow laboratory repeat policy 						
	<ol style="list-style-type: none"> 2. Review instrument printouts for result reasonableness, questionable results are repeated. 						
	<ol style="list-style-type: none"> 3. Review instrument printouts for LIH indices and any flags. 						

IX. Limitations, Reportable Range, Calculations, Reference Range, Interpretation and Result Reporting

A	Limitations
	<ol style="list-style-type: none"> 1. No clinical significant interference has been found in samples spiked with: <ol style="list-style-type: none"> a. Bilirubin: up to 30 mg/dL Bilirubin b. Hemolysis: up to 400 mg/dL Hemolysate. c. Lipemia: up to 750 mg/dL Triglycerides
	<ol style="list-style-type: none"> 2. Sensitivity: <ol style="list-style-type: none"> a. 2.0 ug/mL b. This represents the lowest concentration of vancomycin that can be distinguished from 0 ug/mL with 95% confidence.

3. Specificity:

- a. The compounds listed in the following table do not interfere with the Emit 2000 Vancomycin Assay when tested in the presence 20 ug/mL vancomycin. Levels tested were at or above maximum physiological or pharmacological concentrations.

Compounds that Do Not Interfere	
Acyclovir	Furosemide
Amikacin	Fusidic Acid
Amphotericin B	Gentamicin
Aztreonam	Imipenem
Caffeine	Methicillin
CDP-1	Metronidazole
Cefazoline	Netilmicin
Cefotaxime	Nitroprusside
Chloramphenicol	Penicillin G*
Ciprofloxacin	Pentamidine
Cisplatin	Phenobarbital
Clindamycin	Rifampin
Cyclosporine	Salicylate
Digoxin	Sulphamethoxazole
Epinephrine	Theophylline
Erythromycin	Trimethoprim
Ethacrynic Acid	Tobramycin
Flucytosine	

B AMR & Reportable RangeAMR

2.0 - 50.0 ug/mL

Reportable Range

2.0 - 500.0 ug/mL

Results outside the linear limits are reported as such.

C Calculations

All calculations are automatically performed by the Beckman Coulter AU680 Analyzer and RILIS.

D Reference Range

Peak: 20.0 - 40.0 ug/mL

Random: Not Established

Trough: 10.0 - 20.0 ug/mL

Therapeutic Drug Monitoring: The therapeutic drug dose and date/time and TDM specimen collection date/time are documented in the electronic medical record, KP-Health Connect, for the treating clinician's/pharmacist's assessment.


E Critical Values

None

F	Early Notification Values
	Trough: ≥ 21.0 ug/mL
G	Result Reporting & Interpretation
	1. Confirm ALL flags and indices are properly addressed before reporting any result.
	2. Report Vancomycin results in ug/mL and to one decimal place.
	3. Review the instrument printout for result reasonableness, LIH indices and any flags.
	4. If any index shows ABN, visually check the sample appearance to confirm the index ABN is correct. Extreme lipemia, hemolysis, or icterus can show all indices as "ABN". <ol style="list-style-type: none"> a. Severe hemolysis causes unpredictable increase or decrease in vancomycin. b. Refer to SFOFCD-0411 "AU680 Comment Codes for Reporting Interference due to Lipemia, Icterus, and Hemolysis"
	5. If testing was performed on SST/PST, append TDMSST as Result Comment.

X. Corrective Action

A	QC Out of Acceptable Range
	1. Review data and LJ charts. If an out of control value appears to be random error, repeat control on new QC aliquot.
	2. Refer to SFOWI-0218 and SFOSOP-0288 for additional QC troubleshooting steps.
	3. Do not use the instrument for patient tests until issues are resolved. Beckman Coulter Tech Support is available at 1-800-854-3633.
B	Instrument Warning or Error Flag Displayed
	1. See Reference Manual for troubleshooting steps.
	2. Do not use the instrument for patient tests until issues are resolved. Beckman Coulter Tech Support is available at 1-800-854-3633.

AU680 TDM Vancomycin	SFO-WI.1303	Page 8 of 8
 KAISER PERMANENTE KFH San Francisco Laboratory	Chemistry 2425 Geary Boulevard San Francisco, CA 94115	

XI. Associated Documents and Records

SFOFCD-0407
SFOFCD-0408
SFOFCD-0411
SFOFCD-0412
SFOWI-0218
SFOWI-1268
SFOSOP-0288

XII. References

1. RWLQCWI-2090 rev.4 AU 680 TDM Vancomycin
2. Beckman Coulter Instructions for Use: Vancomycin, CLSIOSR4W229.02 March 2012.
3. Vancomycin Package Insert dated June 2011.